Access - Pricing - HEOR Courses

Learn the fundamentals of market access, pharma pricing, health economics, HTA and RWE


The below CELforPharma courses are designed to accelerate your learning curve in disciplines that are critical in the process of optimising patient access.

In just 1 or 2 days, you will gain invaluable insights and practical knowledge from the expertise of industry thought leaders. The small class sizes and interactive programmes ensure that you will also learn from sharing experiences with your international peers.

 

AI IN MARKET ACCESS:

The AI for Pharma Market Access Course
With Dr. Stefan Walzer
Dr. Stefan Walzer

🎓 What you will learn:

  1. Master the essentials of AI in pharma market access: Understand key terminology, explore the transformative impact of AI, and tackle industry-specific challenges.
  2. Integrate AI-driven tools with confidence: Learn how to seamlessly incorporate AI into market access processes to boost efficiency and achieve superior outcomes.
  3. Discover the best AI systems for your needs: Get an overview of available AI technologies, along with their pros and cons, tailored to pharma market access applications.
  4. Gain hands-on experience with AI in action: Participate in practical exercises using AI-driven tools for market access planning, systematic literature reviews, dossier writing, and payer negotiations.
    (Features a real-life prostate cancer case study to simulate and solve real-world challenges across the market access lifecycle.)
  5. Learn from your peers in pharma market access: Benefit from peer insights as they will share their challenges, experiences, and innovative solutions.

MARKET ACCESS IN EUROPE:

Understanding Pharma Market Access & Payers in Europe
With Dr. Nick Proctor
Dr. Nick Proctor

🎓 What you will learn:

  1. The patterns in pricing & reimbursement systems and processes in France, Germany, Italy, Spain and the UK.
  2. Market access challenges and opportunities in these countries.
  3. How to differentiate between categories of payers.
  4. Payer archetypes and the drivers of their decision-making processes.
  5. The market access plan and process, and the contributions of internal stakeholders across functions.
  6. The types of Managed Entry Agreements that are used by payers and pharma to mitigate risk.

MARKET ACCESS IN THE US:

Understanding Pharma Market Access in the US
With Dr. Nick Proctor & Louisa Oliver Byrne
Dr. Nick Proctor
Louisa Oliver

🎓 What you will learn:

  1. The structure and key players of US Managed Care systems, and how they compare with other global systems.
  2. The scope of medical benefit and how to navigate the pricing and access control mechanisms in this system.
  3. The role and significance of Pharmacy Benefit Managers (PBMs) and how to navigate the pricing and access control mechanisms in the pharmacy benefit system.
  4. The potential future impact of reforms such as the Inflation Reduction Act and increased PBM transparency.
  5. Strategies for navigating towards successful market access and how to deal with the most common challenges along the way.

VALUE PRICING:

How to Price Better Than Your Competitors for Successful Market Access
Essential Insights, Principles & Techniques
With Gary Johnson & Sam Johnson
Gary Johnson
Sam Johnson

🎓 What you will learn:

  1. An overview of payer types and of national pricing & market access systems around the world.
  2. The concepts and language of pharma pricing and market access that confuse many executives.
  3. The difference between setting prices and defending prices with health economics.
  4. Evidence-based research techniques for getting the most accurate feedback from payers about your product’s profile.
  5. How to analyse past payer behaviour to predict future pricing behaviour.
  6. How to anticipate the impact of the international pricing system on your prices around the globe. 

REAL WORLD EVIDENCE:

Generating RWE for Optimising Market/Patient Access
With Prof. Dr. Thomas Wilke
Prof. Dr. Thomas Wilke

🎓 What you will learn:

  1. The expectations of external stakeholders regarding RWE along the product lifecycle.
  2. The fundamental concepts, methodologies and research techniques of RWE in the context of optimising Market Access.
  3. Types of data and their strengths & weaknesses.
  4. Critical success factors of a RWE study.
  5. How to prepare for new developments in RWE generation. 

HEALTH ECONOMICS:

Health Economics for Non-Health-Economists
With Prof. Dr. Lieven Annemans

🎓 What you will learn:

  1. The logic and math behind QALYs, ICERs, decision-trees and Markov models.
  2. How external stakeholders use and challenge health economic evidence.
  3. To distinguish good from bad health economic evaluation studies (of your brand or its competitors).
  4. Key principles of cost-effectiveness analysis and Budget Impact Analysis.
  5. The role of health economic evaluations in clinical research, pricing & reimbursement decisions, and post-launch.

HEALTH TECHNOLOGY ASSESSMENT:

Critical New HTA Developments in Europe: Challenges & Solutions
With Prof. Dr. Lieven Annemans

🎓 What you will learn:

  1. The different types of HTAs in Europe.
  2. How to address the broad and evolving array of assessment criteria in Europe.
  3. How to optimise clinical evidence generation for HTA bodies.
  4. How to use Real World Data for HTA purposes.
  5. How to prepare for the new Joint Clinical Assessment (JCA) in the EU.

Are you ready to take your career in the pharmaceutical industry to the next level? 🚀

Discover CELforPharma's complete course portfolio, including topics you work on in cross-functional teams:

Course finder

WANT TO ORGANISE AN IN-COMPANY COURSE?

CELforPharma in-company trainings